Back to top

Citi Sticks to Their Buy Rating for Hikma Pharmaceuticals (HIK)

In a report released today, Giang Nguyen from Citi reiterated a Buy rating on Hikma Pharmaceuticals, with a price target of £18.70. According to Ti...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Hikma Pharmaceuticals Plc (HKMPF)